Synmosa Collaborates with InnoPharmax to Branch Out into Production of API

Date:2016.03.24

Synmosa Biopharma (TPEx:4114) today announced a plan to collaborate with InnoPharmax Inc. (TPEx:4172) in a joint acquisition of Seven Star Pharmaceutical Co., Ltd. The major investment deal, which consists of acquiring a 70% majority stake in Seven Star Pharma at a valuation of NT$95 per share, allows Synmosa to officially branch out into the production of pharmaceutical raw ingredients and achieve full vertical integration, highlighting the company's new direction for development in the biopharmaceutical industry.